



          Fourth Quarter &
        

          Full Year 2022
        

          Financial Results
        

          February 23rd, 2023
        



          © 2023 M oderna, Inc. All rights reserved.
        





          Forward-looking statements and disclaimer
        

          This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: anticipated sales, including the timing of sales, under advance purchase agreements in
        

          2023, which may not be realized; expected new contracts for COVID-19 vaccines; Moderna's expectations regarding an endemic,
        

          commercial market for COVID-19 and its preparations for and ability to effectively compete in such a market; Moderna's assumptions regarding potential 2023 U.S. COVID-19 vaccination volume, including vaccination rate assumptions; the medical burden of endemic COVID-19; Moderna's ability to leverage commercial infrastructure for a potential RSV vaccine launch in 2024; Moderna's plants to file a biologics license application (BLA) for mRNA-1345 (RSV) in the first half of 2023, and anticipated timing for regulatory action; the
        

          timing of interim data from Moderna's Northern Hemisphere flu efficacy study; Moderna's plans with respect to its personalized cancer vaccine candidate, including its plans to initiate a Phase 3 study in adjuvant melanoma in 2023 and rapidly expand to additional
        

          tumor types, including non-small cell lung cancer; anticipated publication of full Phase 2 PCV data in 2023; participant enrollment in
        

          Moderna's clinical trials, including enrollment demographics and timing; the timing of data from Moderna's ongoing clinical trials; early signs of potential clinical benefit for PA; Moderna's capital allocation priorities, including anticipated spending on R&D for 2023; and Moderna's 2023 financial framework. In some cases, forward-looking statements can be identified by terminology such as "will,"
        

          "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential,"
        

          "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or impli ed by
        

          these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2021
        

          and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forwar d-looking
        

          statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation
        

          Financial figures as of and for the year ended December 31, 2022 remain subject to audit. Financial figures for the quarterly period
        

          ended December 31, 2022 and as of and for the quarterly period ended September 31, 2022 are unaudited.
        






                2
              



                © 2023 M oderna, Inc. All rights reserved.
              








          4Q22 earnings call agenda
        



          Business Review
        

          Stéphane Bancel, CEO
        

          R&D/Clinical Programs
        

          Stephen Hoge, M.D., President
        

          Commercial Market
        

          Arpa Garay, CCO
        

          Financials
        

          Jamey Mock, CFO
        

          Looking Forward
        

          Stéphane Bancel, CEO
        






                3
              



                © 2023 M oderna, Inc. All rights reserved.
              








          Fiscal year 2022 financial highlights
        

          Fiscal year 2022 GAAP financial results
        




                Revenue:
              



                Net income:
              



                Earnings
              



                Cash and
              





                $19.3 billion
              



                $8.4 billion
              



                per share:
              



                investments:
              









                $20.12
              



                $18.2 billion
              




          Capital allocation highlights
        




                Reinvest in the
              



                External investment
              



                Return capital to
              





                business
              



                opportunities (licenses and/or
              



                shareholders
              





• $3.3 billion R&D
              



                M&A)
              



                Repurchased 23 million
              









• $1.1 billion SG&A
              



                2022: Metagenomi, Carisma
              



                shares for $3.3 billion in 2022
              





                2023: OriCiro, CytomX, LifeEdit
              



                (avg. price ~$143/share)
              





• $0.4 billion Capital
              















                expenditures
              













                4
              



                © 2023 M oderna, Inc. All rights reserved.
              








          Moderna 2022




COVID booster (mRNA-1273.214 & mRNA-1273.222)
        

          Two authorized Omicron-targeting bivalent vaccines; mRNA-1273.222 on market in less than two months
        

          RSV vaccine (mRNA-1345)


          Phase 1 to Phase 3 in 13 months; pivotal Phase 3 trial met primary efficacy endpoint
        

          Personalized Cancer Vaccine (PCV) (mRNA-4157)


          First demonstration of efficacy for an mRNA cancer treatment in a randomized clinical trial
        

          Propionic acidemia (PA) (mRNA-3927)


          Decrease in number of metabolic decompensation events with generally well -tolerated profile
        

          Inhaled Pulmonary Therapeutics
        

          First inhaled mRNA candidate enters clinic in partnership with Vertex; marks seventh Moderna modality in human studies
        

          Environmental, Social, and Governance
        

          Delivered our first ESG report and hosted inaugural ESG day
        


Attachments


            Original Link
          

            Original Document
          

            Permalink
          



Disclaimer
Moderna Inc. published this content on 23 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2023 14:03:06 UTC.
      

